Further research is necessary to establish the specific consequences of GM-CSF in MMP-2 deficiency, and to test the possibility of targeting GM-CSF to manage inflammation and prevent bone loss in MONA. This evidence concerns the gene CSF2 and hyperinsulinemic hypoglycemia, familial, 4.